Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CCR9 | P51686 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 3/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525803 | 0.94 | ALDH1A1 (0.48) | LMNATP53MAPTHTTKMT2A | |
| SCHEMBL3527669 | 0.91 | LMNA (0.48) | LMNATP53MAPTHTTKMT2A | |
| SCHEMBL3527490 | 0.90 | LMNA (0.53) | LMNATP53MAPTHTTKMT2A | |
| SCHEMBL3523698 | 0.90 | ERBB2 (0.50) | LMNAMAPTHTTKMT2ACCR9 | |
| SCHEMBL3526734 | 0.89 | CCR9 (0.49) | CCR9ALDH1A1CCR2 | |
| SCHEMBL3524039 | 0.89 | CCR9 (0.49) | LMNATP53MAPTHTTKMT2A | |
| SCHEMBL3525551 | 0.89 | CCR9 (0.48) | LMNATP53MAPTHTTKMT2A | |
| SCHEMBL3523501 | 0.89 | CCR2 (0.47) | LMNATP53MAPTHTTKMT2A | |
| SCHEMBL3525286 | 0.88 | CCR2 (0.43) | LMNATP53MAPTHTTKMT2A | |
| SCHEMBL3524514 | 0.88 | HSD17B2 (0.53) | CCR9CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436040-B2 | Method of treating conditions involving PPAR-receptors with indole compounds | LABORATOIRES FOURNIER S.A. (FR) | 2013-05-07 | — | — | US | disclosed |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | LABORATORIES FOURNIER S.A. (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7795297-B2 | Indole compounds, method of preparing them and uses thereof | LABORATORIES FOURNIER S.A. (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LIPG, GPR119, IAPP | LMNA 849/4885TP53 3755/4885MAPT 214/4885 |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | GPR119, PPARA, PPARG | LMNA 1980/4885TP53 2497/4885MAPT 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.